*Simultaneous French interpretation will be available
*Simultaneous French interpretation will be available |
|
For decades, the development of an effective new tuberculosis vaccine has remained one of the world’s most urgent public health priorities. Today, with promising vaccine candidates advancing through the pipeline, global momentum around new TB vaccines is growing rapidly. Join us for a timely webinar bringing together leaders from the TB and immunization communities to explore the future of TB vaccines. The session will feature new survey findings on vaccine readiness from the Sabin and the STOP TB Partnership communities, expert perspectives on leading vaccine candidates including M72/AS01E and Mtbvac, and a discussion around what countries can consider to prepare for future introduction and equitable access. 📅 Date: Wednesday, June 10 ⏰ Time: 12 - 1:30 PM UTC (find your local time) |
During the webinar, you'll hear from... |
STOP TB Partnership and Sabin Representatives Share key findings from the joint Sabin Vaccine Institute and STOP TB Partnership survey on TB vaccine readiness, highlighting perspectives from both the TB and immunization communities across countries and regions. The discussion will explore current levels of preparedness, perceived challenges and opportunities for future TB vaccine introduction, and the importance of cross-sector collaboration as next-generation TB vaccines continue to advance. Dr. Alemnew Dagnew, Gates MRI Dr. Dagnew will provide an overview of the M72 TB vaccine candidate and its potential implications for the future of tuberculosis prevention globally. The session will explore recent progress in clinical development, the significance of ongoing investments and partnerships, and what countries, immunization programs, and global health stakeholders should begin considering as preparations for potential vaccine introduction advance. Dr. Rolando Pajon, Biofabri Dr. Pajon will share insights on Mtbvac and its role within the evolving TB vaccine pipeline. His presentation will highlight the scientific approach behind the candidate, recent progress in development, and key considerations for future implementation and access as the global health community prepares for next-generation TB vaccines. |
Key Takeaways: |
✅ Insights from TB and immunization communities on vaccine readiness and introduction planning ✅ Updates on the evolving TB vaccine pipeline, including M72/AS01E and Mtbvac ✅ Key considerations for preparing countries and communities for next-generation TB vaccines Join us for a timely discussion on the future of TB prevention and the path toward equitable vaccine access globally. |
|
This webinar is supported by an Unrestricted Educational Grant from GSK Global Health to Sabin |
\n\n\n LOCATION: END:VEVENT END:VCALENDAR